NCT02483312View on ClinicalTrials.gov

A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions

Acute Myeloid Leukemia

Interventions

BIOLOGICAL

IL-12

Trial Locations (1)

M5G 2M9

Princess Margaret Centre Centre, Toronto

Sponsors

Collaborators (1)

Ozmosis Research Inc.

All Listed Sponsors

collaborator

Ozmosis Research Inc.

INDUSTRY

lead

University Health Network, Toronto

OTHER